- Home
- REVBW vs MAS Comparison
REVBW vs MAS Comparison
Compare REVBW & MAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- MAS
- Stock Information
- Founded
- REVBW N/A
- MAS 1929
- Country
- REVBW United States
- MAS United States
- Employees
- REVBW 9
- MAS N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- MAS Industrial Specialties
- Sector
- REVBW Health Care
- MAS Industrials
- Exchange
- REVBW Nasdaq
- MAS Nasdaq
- Market Cap
- REVBW N/A
- MAS N/A
- IPO Year
- REVBW 2020
- MAS N/A
- Fundamental
- Price
- REVBW $0.01
- MAS $78.40
- Analyst Decision
- REVBW
- MAS Buy
- Analyst Count
- REVBW 0
- MAS 15
- Target Price
- REVBW N/A
- MAS $84.82
- AVG Volume (30 Days)
- REVBW N/A
- MAS 1.7M
- Earning Date
- REVBW N/A
- MAS 10-29-2024
- Dividend Yield
- REVBW N/A
- MAS 1.48%
- EPS Growth
- REVBW N/A
- MAS 2.74
- EPS
- REVBW N/A
- MAS 3.76
- Revenue
- REVBW N/A
- MAS $7,882,000,000.00
- Revenue This Year
- REVBW N/A
- MAS N/A
- Revenue Next Year
- REVBW N/A
- MAS $0.93
- P/E Ratio
- REVBW N/A
- MAS $20.87
- Revenue Growth
- REVBW N/A
- MAS N/A
- 52 Week Low
- REVBW N/A
- MAS $58.89
- 52 Week High
- REVBW N/A
- MAS $86.70
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- MAS 35.69
- Support Level
- REVBW N/A
- MAS $78.02
- Resistance Level
- REVBW N/A
- MAS $82.04
- Average True Range (ATR)
- REVBW 0.00
- MAS 1.62
- MACD
- REVBW 0.00
- MAS -0.29
- Stochastic Oscillator
- REVBW 0.00
- MAS 8.62
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).